{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:17:04Z","timestamp":1789777024792,"version":"4.0.1"},"reference-count":126,"publisher":"Bentham Science Publishers Ltd.","issue":"41","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,1,31]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Serotonin reuptake inhibitors (SRIs) and cognitive-behavioral psychotherapy\n(CBT) are first-line treatments for obsessive-compulsive disorder (OCD). However,\na significant proportion of patients do not respond satisfactorily to first-choice treatments.\nSeveral options have been investigated for the management of resistant patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aim of the present paper is to systematically review the available literature\nconcerning the strategies for the treatment of resistant adult patients with OCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>We first reviewed studies concerning the definition of treatment-resistant OCD;\nwe then analyzed results of studies evaluating several different strategies in resistant patients.\nWe limited our review to double-blind, placebo-controlled studies performed in\nadult patients with OCD whose resistance to a first adequate (in terms of duration and\ndosage) SRI trial was documented and where outcome was clearly defined in terms of decrease\nin Yale-Brown Obsessive-Compulsive Scale (YBOCS) scores and\/or response\/\nremission rates (according to the YBOCS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified five strategies supported by positive results in placebo-controlled\nrandomized studies: 1) antipsychotic addition to SRIs (16 RCTs, of them 10 positive; 4\nhead-to-head RCTs); among antipsychotics, available RCTs examined the addition of\nhaloperidol (butyrophenone), pimozide (diphenyl-butylpiperidine), risperidone (SDA: serotonin-\ndopamine antagonist), paliperidone (SDA), olanzapine (MARTA: multi-acting\nreceptor targeted antipsychotic), quetiapine (MARTA) and aripiprazole (partial dopamine\nagonist); 2) CBT addition to medication (2 positive RCTs); 3) switch to intravenous\nclomipramine (SRI) administration (2 positive RCTs); 4) switch to paroxetine (SSRI: selective\nserotonin reuptake inhibitor) or venlafaxine (SNRI: serotonin-norepinephrine reuptake\ninhibitor) when the first trial was negative (1 positive RCT); and 5) the addition of\nmedications other than an antipsychotic to SRIs (18 RCTs performed with several different\ncompounds, with only 4 positive studies).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Treatment-resistant OCD remains a significant challenge to psychiatrists. To\ndate, the most effective strategy is the addition of antipsychotics (aripiprazole and risperidone)\nto SRIs; another effective strategy is CBT addition to medications. Other strategies,\nsuch as the switch to another first-line treatment or the switch to intravenous administration\nare promising but need further confirmation in double-blind studies. The addition of\nmedications other than antipsychotics remains to be studied, as several negative studies\nexist and positive ones need confirmation (only 1 positive study).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867325666171222163645","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T06:09:41Z","timestamp":1514268581000},"page":"5647-5661","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy"],"prefix":"10.2174","volume":"25","author":[{"given":"Umberto","family":"Albert","sequence":"first","affiliation":[{"name":"Rita Levi Montalcini Department of Neuroscience, University of Turin, Italy; A.O.U. San Luigi Gonzaga of Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Marazziti","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Clinica e Sperimentale, Section of Psychiatry, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Di Salvo","sequence":"additional","affiliation":[{"name":"Rita Levi Montalcini Department of Neuroscience, University of Turin, Italy; A.O.U. San Luigi Gonzaga of Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Solia","sequence":"additional","affiliation":[{"name":"Rita Levi Montalcini Department of Neuroscience, University of Turin, Italy; A.O.U. San Luigi Gonzaga of Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Rosso","sequence":"additional","affiliation":[{"name":"Rita Levi Montalcini Department of Neuroscience, University of Turin, Italy; A.O.U. San Luigi Gonzaga of Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maina","sequence":"additional","affiliation":[{"name":"Rita Levi Montalcini Department of Neuroscience, University of Turin, Italy; A.O.U. San Luigi Gonzaga of Orbassano, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"2","volume":"58","author":"March J.","year":"1997","unstructured":"Frances A, Carpenter D, Kahn D. The expert consensus guidelines series. treatment of obsessive-compulsive disorder.","journal-title":"J Clin Psychiatry"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","volume":"19","author":"Baldwin D.S.","year":"2005","unstructured":"Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.","journal-title":"J Psychopharmacol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"Baldwin D.S.","year":"2014","unstructured":"Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, Malizia A, McCrone P, Nabarro D, O\u2019Neill C, Scott J, van der Wee N, Wittchen HU. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.","journal-title":"J Psychopharmacol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/070674370605100104","volume":"51","author":"","year":"2006","unstructured":". Clinical practice guidelines. Management of anxiety disorders.","journal-title":"Can J Psychiatry"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"Bandelow B.","year":"2008","unstructured":"Zohar J, Hollander E, Kasper S, M\u00f6ller HJ. Zohar, J.; Hollander, E.; Kasper, S.; M\u00f6ller, H.J.; Bandelow, B.; Allgulander, C.; Ayuso-Gutierrez, J.; Baldwin, DS.; Buenvicius, R.; Cassano, G.; Fineberg, N.; Gabriels, L.; Hindmarch, I.; Kaiya, H.; Klein, D.F.; Lader, M.; Lecrubier, Y.; L\u00e9pine, JP.; Liebowitz, MR.; Lopez-Ibor, J.J.; Marazziti, D.; Miguel, E.C.; Oh, K.S.; Preter, M.; Rupprecht, R.; Sato, M.; Starcevic, V.; Stein, D.J.; van Ameringen, M.; Vega, J. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision.","journal-title":"World J Biol Psychiatry"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","volume":"16","author":"Bandelow B.","year":"2012","unstructured":". Sher, L.; Bunevicius, R.; Hollander, E.; Kasper, S.; Zohar, J.; M\u00f6ller, H.J. WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder in primary care.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"Katzman M.A.","year":"2014","unstructured":". Bleau. P.; Blier, P.; Chokka, P.; Kjernisted, K.; Van Ameringen, M.; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada\/Association Canadienne des troubles anxieux and McGill University; Antony, M.M.; Bouchard, S.; Brunet, A.; Flament, M.; Grigoriadis, S.; Mendlowitz, S.; O\u2019Connor, K.; Rabheru, K.; Richter, P.M.; Robichaud, M.; Walker. J.R. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.","journal-title":"BMC Psychiatry"},{"key":"ref=10","first-page":"CD001765","volume":"23","author":"Soomro G.M.","year":"2008","unstructured":"Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors vs placebo for obsessive-compulsive disorder (OCD).","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004850-200507000-00005","volume":"20","author":"Fineberg N.A.","year":"2005","unstructured":"Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SSRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study.","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=12","first-page":"16","volume":"54","author":"Goodman W.K.","year":"1993","unstructured":"McDougle CJ, Barr LC, Aronson SC, Price LH. Biological approaches to treatment-resistant obsessive compulsive disorder.","journal-title":"J Clin Psychiatry"},{"key":"ref=13","first-page":"6","author":"Seibel P.J.","year":"2014","unstructured":"Hollander E. Management of obsessive-compulsive disorder.","journal-title":"F1000Prime Rep"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1177\/1039856215590027","volume":"23","author":"Castle D.","year":"2015","unstructured":"Bosanac P, Rossell S. Treating OCD: what to do when first-line therapies fail.","journal-title":"Australas Psychiatry"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.encep.2013.11.002","volume":"41","author":"Ammar G.","year":"2015","unstructured":"Naja WJ, Pelissolo A. Treatment-resistant anxiety disorders: a literature review of drug therapy strategies.","journal-title":"Encephale"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","volume":"11","author":"Bloch M.H.","year":"2006","unstructured":"Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.","journal-title":"Mol Psychiatry"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1017\/S1461145712000740","volume":"16","author":"Dold M.","year":"2013","unstructured":"Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","volume":"14","author":"Veale D.","year":"2014","unstructured":"Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.","journal-title":"BMC Psychiatry"},{"key":"ref=19","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv047","volume":"18","author":"Dold M.","year":"2015","unstructured":"Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials.","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1017\/S0033291714000981","volume":"44","author":"Kisely S.","year":"2014","unstructured":"Hall K, Siskind D, Frater J, Olson S, Crompton D. Deep brain stimulation for obsessive-compulsive disorder: a systematic review and meta-analysis.","journal-title":"Psychol Med"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/08039488.2016.1162846","volume":"70","author":"Naesstr\u00f6m M.","year":"2016","unstructured":"Blomstedt P, Bodlund O. A systematic review of psychiatric indications for deep brain stimulation, with focus on major depressive and obsessive-compulsive disorder.","journal-title":"Nord J Psychiatry"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jad.2017.03.033","volume":"215","author":"Zhou D.D.","year":"2017","unstructured":"Wang W, Wang GM, Li DQ, Kuang L. An updated meta-analysis: short-term therapeutic effects of repeated transcranial magnetic stimulation in treating obsessive-compulsive disorder.","journal-title":"J Affect Disord"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00702-016-1642-2","volume":"124","author":"Cimprianu C.L.","year":"2017","unstructured":"Strube W, Falkai P, Palm U, Hasan A. Vagus nerve stimulation in psychiatry: a systematic review of the available evidence.","journal-title":"J Neural Transm"},{"key":"ref=24","first-page":"83","volume":"44","author":"Albert U.","year":"2002","unstructured":"Bergesio C, Pessina E, Maina G, Bogetto F. Management of treatment resistant obsessive-compulsive disorder. Algorithms for pharmacotherapy.","journal-title":"Panminerva Med"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4088\/JCP.v65n1015","volume":"65","author":"Pallanti S.","year":"2004","unstructured":"Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder.","journal-title":"J Clin Psychiatry"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1017\/S109285290000225X","volume":"9","author":"Husted D.S.","year":"2004","unstructured":"Shapira NA. A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation.","journal-title":"CNS Spectr"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11587860-000000000-00000","volume":"25","author":"Abudy A.","year":"2011","unstructured":"Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder.","journal-title":"CNS Drugs"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4088\/JCP.v66n1209","volume":"66","author":"Tolin D.F.","year":"2005","unstructured":"Abramowitz JS, Diefenbach GJ. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale.","journal-title":"J Clin Psychiatry"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/wps.20299","volume":"15","author":"Mataix-Cols D.","year":"2016","unstructured":"Fern\u00e1ndez de la Cruz L, Nordsletten AE, Lenhard F, Isomura K, Simpson HB. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in Obsessive-Compulsive Disorder: A Delphi survey.","journal-title":"World Psychiatry"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","volume":"15","author":"Bloch M.H.","year":"2010","unstructured":"McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder.","journal-title":"Mol Psychiatry"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1600-0447.2008.01257.x","volume":"118","author":"Ghaemi S.N.","year":"2008","unstructured":"Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks.","journal-title":"Acta Psychiatr Scand"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4088\/JCP.v69n0816","volume":"69","author":"Salvi V.","year":"2008","unstructured":"Fagiolini A, Swartz HA, Maina G, Frank E. The use of antidepressants in bipolar disorder.","journal-title":"J Clin Psychiatry"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1600-0447.1997.tb09929.x","volume":"96","author":"De Haan E.","year":"1997","unstructured":"van Oppen P, van Balkom AJ, Spinhoven P, Hoogduin KA, Van Dyck R. Prediction of outcome and early vs late improvement in OCD patients treated with cognitive behavior therapy and pharmacotherapy.","journal-title":"Acta Psychiatr Scand"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/10673220216215","volume":"10","author":"McDonough M.","year":"2002","unstructured":"Kennedy N. Pharmacological management of obsessive-compulsive disorder: a review for clinicians.","journal-title":"Harv Rev Psychiatry"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1017\/S1121189X00002050","volume":"15","author":"Albert U.","year":"2006","unstructured":"Maina G, Saracco P, Bogetto F. Multifamily psychoeducational Intervention (MPI) for obsessive-compulsive study: a pilot study.","journal-title":"Epidemiol Psichiatr Soc"},{"key":"ref=38","first-page":"382","volume":"3","author":"Maina G.","year":"2006","unstructured":"Saracco P, Albert U. Family-focused treatments for obsessive-compulsive disorder.","journal-title":"Clinical Neuropsychiatry"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1176\/ps.2007.58.7.970","volume":"58","author":"Albert U.","year":"2007","unstructured":"Salvi V, Saracco P, Bogetto F, Maina G. Health-related quality of life among first degree relatives of patients with obsessive-compulsive disorder in Italy.","journal-title":"Psychiatr Serv"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1440-1819.2011.02240.x","volume":"65","author":"Grover S.","year":"2011","unstructured":"Dutt A. Perceived burden and quality of life of caregivers in obsessive-compulsive disorder.","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/brief-treatment\/mhg017","volume":"3","author":"van Noppen B.","year":"2003","unstructured":"Steketee G. Family response and multifamily behavioral treatment for obsessive-compulsive disorder.","journal-title":"Brief Treat Crisis Interv"},{"key":"ref=42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"Moher D.","year":"2009","unstructured":"Liberati A, Tetzlaff J, Altman DG. Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","journal-title":"PLoS Med"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"Moher D.","year":"2010","unstructured":"Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","journal-title":"Int J Surg"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jad.2004.03.011","volume":"82","author":"Sareen J.","year":"2004","unstructured":"Kirshner A, Lander M, Kjernisted KD, Eleff MK, Reiss JP. Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review.","journal-title":"J Affect Disord"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euroneuro.2006.07.002","volume":"17","author":"Skapinakis P.","year":"2007","unstructured":"Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=46","first-page":"CD008141","volume":"12","author":"Komossa K.","year":"2010","unstructured":"Depping AM, Meyer M, Kissling W, Leucht S. Second-generation antipsychotics for obsessive compulsive disorder.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","volume":"306","author":"Maher A.R.","year":"2011","unstructured":"Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. A systematic review and meta-analysis.","journal-title":"JAMA"},{"key":"ref=48","first-page":"1023","volume":"1","author":"Albert U.","year":"2014","unstructured":"De Cori D, Bogetto F, Maina G. Treatment-resistant Obsessive-Compulsive Disorder (OCD): focus on antipsychotic augmentation to SRIs.","journal-title":"Austin J Psychiatry Behav Sci"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00213-014-3516-3","volume":"231","author":"Ducasse D.","year":"2014","unstructured":"Boyer L, Michel P, Loundou A, Macgregor A, Micoulaud-Franchi JA, Courtet P, Abbar M, Leboyer M, Fond G. D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis.","journal-title":"Psychopharmacology"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.psychres.2014.12.003","volume":"227","author":"Fineberg N.A.","year":"2015","unstructured":"Reghunandanan S, Simpson HB, Phillips KA, Richter MA, Matthews K, Stein DJ, Sareen J, Brown A, Sookman D. Accreditation Task Force of The Canadian Institute for Obsessive Compulsive Disorders. Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults.","journal-title":"Psychiatry Res"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/YIC.0000000000000127","volume":"31","author":"Albert U.","year":"2016","unstructured":"Carmassi C, Cosci F, De Cori D, Di Nicola M, Ferrari S, Poloni N, Tarricone I, Fiorillo A. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review.","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1176\/ajp.147.5.652","volume":"147","author":"McDougle C.J.","year":"1990","unstructured":"Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.","journal-title":"Am J Psychiatry"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","volume":"51","author":"McDougle C.J.","year":"1994","unstructured":"Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.","journal-title":"Arch Gen Psychiatry"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881105056640","volume":"21","author":"Fineberg N.A.","year":"2006","unstructured":"Gale TM, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder.","journal-title":"J Psychopharmacol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.genhosppsych.2012.10.004","volume":"35","author":"Albert U.","year":"2013","unstructured":"Aguglia A, Chiarle A, Bogetto F, Maina G. Metabolic syndrome and obsessive-compulsive disorder: a naturalistic Italian study.","journal-title":"Gen Hosp Psychiatry"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004850-200205000-00004","volume":"17","author":"Atmaca M.","year":"2002","unstructured":"Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.v65n0803","volume":"65","author":"Denys D.","year":"2004","unstructured":"de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized,placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.","journal-title":"J Clin Psychiatry"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-244X-5-5","volume":"5","author":"Carey P.D.","year":"2005","unstructured":"Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study.","journal-title":"BMC Psychiatry"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004850-200507000-00005","volume":"20","author":"Fineberg N.A.","year":"2005","unstructured":"Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study.","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0b013e318185e735","volume":"28","author":"Kordon A.","year":"2008","unstructured":"Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.","journal-title":"J Clin Psychopharmacol"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JCP.0b013e3182367aee","volume":"31","author":"Diniz J.B.","year":"2011","unstructured":"Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.","journal-title":"J Clin Psychopharmacol"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","volume":"57","author":"McDougle C.J.","year":"2000","unstructured":"Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.","journal-title":"Arch Gen Psychiatry"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S1461145703003730","volume":"6","author":"Hollander E.","year":"2003","unstructured":"Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","volume":"15","author":"Erzegovesi S.","year":"2005","unstructured":"Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","volume":"70","author":"Simpson H.B.","year":"2013","unstructured":"Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.","journal-title":"JAMA Psychiatry"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/JCP.0b013e31820e3db6","volume":"31","author":"Muscatello M.R.","year":"2011","unstructured":"Bruno A, Pandolfo G, Mic\u00f2 U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.","journal-title":"J Clin Psychopharmacol"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/da.21996","volume":"29","author":"Sayyah M.","year":"2012","unstructured":"Boostani H, Ghaffari SM, Hoseini A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).","journal-title":"Depress Anxiety"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4088\/JCP.v65n0418","volume":"65","author":"Bystritsky A.","year":"2004","unstructured":"Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.","journal-title":"J Clin Psychiatry"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.biopsych.2003.11.010","volume":"55","author":"Shapira N.A.","year":"2004","unstructured":"Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. A double-blind, placebo controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.","journal-title":"Biol Psychiatry"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4088\/JCP.12m08278","volume":"74","author":"Storch E.A.","year":"2013","unstructured":"Goddard AW, Grant JE, De Nadai AS, Goodman WK, Mutch PJ, Medlock C, Odlaug B, McDougle CJ, Murphy TK. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.","journal-title":"J Clin Psychiatry"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4088\/JCP.v66n0610","volume":"66","author":"Li X.","year":"2005","unstructured":"May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.","journal-title":"J Clin Psychiatry"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euroneuro.2008.01.001","volume":"18","author":"Maina G.","year":"2008","unstructured":"Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hup.1169","volume":"26","author":"Selvi Y.","year":"2011","unstructured":"Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.","journal-title":"Hum Psychopharmacol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/2045125314560739","volume":"5","author":"Shoja Shafti S.","year":"2015","unstructured":"Kaviani H. Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial.","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004850-200301000-00004","volume":"18","author":"Maina G.","year":"2003","unstructured":"Albert U, Ziero S, Bogetto F. Antipsychotic augmentation for the treatment-resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4088\/JCP.08m04369","volume":"70","author":"Matsunaga H.","year":"2009","unstructured":"Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.","journal-title":"J Clin Psychiatry"},{"key":"ref=78","first-page":"153","volume":"50","author":"Albert U.","year":"2015","unstructured":"Bogetto F. Treatment of obsessive-compulsive disorder: drugs, psychotherapy or combined treatments?","journal-title":"Riv Psichiatr"},{"key":"ref=79","first-page":"255","volume":"47","author":"Albert U.","year":"2012","unstructured":"Barbaro F, Aguglia A, Maina G, Bogetto F. Combined treatments in obsessive-compulsive disorder: current knowledge and future prospects.","journal-title":"Riv Psichiatr"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4088\/JCP.v60n0904","volume":"60","author":"Simpson H.B.","year":"1999","unstructured":"Gorfinkle KS, Liebowitz MR. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.","journal-title":"J Clin Psychiatry"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1034\/j.1600-0447.2002.01261.x","volume":"106","author":"Kampman M.","year":"2002","unstructured":"Keijsers GP, Hoogduin CA, Verbraak MJ. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine.","journal-title":"Acta Psychiatr Scand"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1016\/S0924-977X(03)92129-8","volume":"13","author":"Albert U.","year":"2003","unstructured":"Maina G, Forner F, Bogetto F. Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIs.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.v65n0708","volume":"65","author":"Tolin D.F.","year":"2004","unstructured":"Maltby N, Diefenbach GJ, Hannan SE, Worhunsky P. Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial.","journal-title":"J Clin Psychiatry"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/da.20260","volume":"24","author":"Storch E.A.","year":"2006","unstructured":"Bagner DM, Geffken GR, Adkins JW, Murphy TK, Goodman WK. Sequential cognitive-behavioral therapy for children with obsessive-compulsive disorder with an inadequate medication response: a case series of five patients.","journal-title":"Depress Anxiety"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.4088\/JCP.v68n1013","volume":"68","author":"Tundo A.","year":"2007","unstructured":"Salvati L, Busto G, Di Spigno D, Falcini R. Addition of cognitive-behavioral therapy for nonresponder to medication for obsessive-compulsive disorder: a naturalistic study.","journal-title":"J Clin Psychiatry"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.janxdis.2011.05.007","volume":"25","author":"Anand N.","year":"2011","unstructured":"Sudhir PM, Math SB, Thennarasu K, Janardhan Reddy YC. Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study.","journal-title":"J Anxiety Disord"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1159\/000336873","volume":"81","author":"Albert U.","year":"2012","unstructured":"Aguglia A, Bogetto F, Cieri L, Daniele M, Maina G, Necci R, Parena A, Salvati L, Tundo A. Effectiveness of cognitive-behavioral therapy addition to pharmacotherapy in resistant obsessive-compulsive disorder: a multicenter study.","journal-title":"Psychother Psychosom"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.4088\/JCP.14m09513","volume":"76","author":"McLean C.P.","year":"2015","unstructured":"Zandberg LJ, Van Meter PE, Carpenter JK, Simpson HB, Foa EB. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.","journal-title":"J Clin Psychiatry"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/15374410903532676","volume":"39","author":"Storch E.A.","year":"2010","unstructured":"Lehmkuhl HD, Ricketts E, Geffken GR, Marien W, Murphy TK. An open trial of intensive family based cognitive-behavioral therapy in youth with obsessive-compulsive disorder who are medication partial or nonresponders.","journal-title":"J Clin Child Adolesc Psychol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/appi.ajp.2007.07091440","volume":"165","author":"Simpson H.B.","year":"2008","unstructured":"Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmachoterapy in obsessive-compulsive disorder.","journal-title":"Am J Psychiatry"},{"key":"ref=91","first-page":"1190","volume":"70","author":"Simpson H.B.","year":"2013","unstructured":"Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.","journal-title":"JAMA"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1017\/S1092852900017119","volume":"13","author":"Boschen M.J.","year":"2008","unstructured":"Drummond LM, Pillay A. Treatment of severe, treatment-refractory obsessive-compulsive disorder: a study of inpatient and community treatment.","journal-title":"CNS Spectr"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jbtep.2009.10.006","volume":"41","author":"Boschen M.J.","year":"2010","unstructured":"Drummond LM, Pillay A, Morton K. Predicting outcome of treatment for severe, treatment resistant OCD in inpatient and community settings.","journal-title":"J Behav Ther Exp Psychiatry"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.brat.2012.01.002","volume":"50","author":"Boschen M.J.","year":"2012","unstructured":"Drummond LM. Community treatment of severe, refractory obsessive-compulsive disorder.","journal-title":"Behav Res Ther"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jbtep.2013.04.002","volume":"44","author":"D\u00e8ttore D.","year":"2013","unstructured":"Pozza A, Coradeschi D. Does time-intensive ERP attenuate the negative impact of comorbid personality disorders on the outcome of treatment-resistant OCD?","journal-title":"J Behav Ther Exp Psychiatry"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jpsychires.2014.05.008","volume":"56","author":"Brennan B.P.","year":"2014","unstructured":"Lee C, Elias JA, Crosby JM, Mathes BM, Andre MC, Gironda CM, Pope Jr, Jenike MA, Fitzmaurice GM, Hudson JI. Intensive residential treatment for severe obsessive-compulsive disorder: Characterizing treatment course and predictors of response.","journal-title":"J Psychiatr Res"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1017\/S1352465815000259","volume":"44","author":"Veale D.","year":"2016","unstructured":"Naismith I. Outcome of intensive cognitive behaviour therapy in a residential setting for people with severe obsessive compulsive disorder: a large open case series.","journal-title":"Behav Cogn Psychother"},{"key":"ref=98","first-page":"625","volume":"12","author":"Vyskocilova J.","year":"2016","unstructured":"Prasko J, Sipek J. Cognitive behavioral therapy in pharmacoresistant obsessive-compulsive disorder.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/070674378402900211","volume":"29","author":"Warneke L.B.","year":"1984","unstructured":". The use of intravenous chlorimipramine in the treatment of obsessive compulsive disorder.","journal-title":"Can J Psychiatry"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/070674378903400902","volume":"34","author":"Warneke L.B.","year":"1989","unstructured":". Intravenous chlorimipramine therapy in obsessive- compulsive disorder.","journal-title":"Can J Psychiatry"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/jnp.4.1.70","volume":"4","author":"Fallon B.A.","year":"1992","unstructured":"Campeas R, Schneier FR, Hollander E, Feerick J, Hatterer J, Goetz D, Davies S, Liebowitz MR. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archpsyc.55.10.918","volume":"55","author":"Fallon B.A.","year":"1998","unstructured":"Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF. Intravenous clomipramine for OCD refractory to oral clomipramine: a controlled study.","journal-title":"Arch Gen Psychiatry"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.jcp.0000195112.24769.b3","volume":"26","author":"Koran L.M.","year":"2006","unstructured":"Aboujaoude E, Ward H, Shapira NA, Sallee FR, Gamel N, Elliott M. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder.","journal-title":"J Clin Psychopharmacol"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4088\/JCP.v63n0908","volume":"63","author":"Pallanti S.","year":"2002","unstructured":"Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.","journal-title":"J Clin Psychiatry"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4088\/JCP.v65n0106","volume":"65","author":"Denys D.","year":"2004","unstructured":"van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.","journal-title":"J Clin Psychiatry"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00004714-199106000-00005","volume":"11","author":"McDougle C.J.","year":"1991","unstructured":"Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.","journal-title":"J Clin Psychopharmacol"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00004714-199108000-00004","volume":"11","author":"Pigott T.A.","year":"1991","unstructured":"Pato MT, L\u2019Heureux F, Hill JL, Grover GN, Bernstein SE, Murphy D. L A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder.","journal-title":"J Clin Psychopharmacol"},{"key":"ref=109","first-page":"11","volume":"12","author":"Pigott T.A.","year":"1992","unstructured":"L\u2019Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder.","journal-title":"J Clin Psychopharmacol"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1176\/ajp.150.4.647","volume":"150","author":"McDougle C.J.","year":"1993","unstructured":"Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, Heninger GR, Price LH. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.","journal-title":"Am J Psychiatry"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1176\/ajp.150.5.819","volume":"150","author":"Grady T.A.","year":"1993","unstructured":"Pigott TA, L\u2019Heureux F, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.","journal-title":"Am J Psychiatry"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1176\/ajp.154.9.1293","volume":"154","author":"Barr L.C.","year":"1997","unstructured":"Goodman WK, Anand A, McDougle CJ, Price LH. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.","journal-title":"Am J Psychiatry"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145799001546","volume":"2","author":"Fux M.","year":"1999","unstructured":"Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study.","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0924-977X(00)00065-1","volume":"10","author":"Dannon P.N.","year":"2000","unstructured":"Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4088\/JCP.v59n0907d","volume":"59","author":"Cor\u00e1-Locatelli G.","year":"1998","unstructured":"Greenberg BD, Martin J, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder.","journal-title":"J Clin Psychiatry"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/10401230490486972","volume":"16","author":"Crockett B.A.","year":"2004","unstructured":"Churchill E, Davidson JR. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder.","journal-title":"Ann Clin Psychiatry"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.euroneuro.2008.01.006","volume":"18","author":"Amiaz R.","year":"2008","unstructured":"Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S1092852912000065","volume":"15","author":"Mowla A.","year":"2010","unstructured":"Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F. Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial.","journal-title":"CNS Spectr"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","volume":"72","author":"Berlin H.A.","year":"2011","unstructured":"Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.","journal-title":"J Clin Psychiatry"},{"key":"ref=120","first-page":"976","volume":"19","author":"Afshar H.","year":"2014","unstructured":"Akuchekian S, Mahaky B, Zarean E. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial.","journal-title":"J Res Med Sci"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0269881111431751","volume":"26","author":"Bruno A.","year":"2012","unstructured":"Mic\u00f2 U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D\u2019Arrigo C, Spina E, Zoccali RA, Muscatello MR. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.","journal-title":"J Psychopharmacol"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","volume":"228","author":"Haghighi M.","year":"2013","unstructured":"Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, Afshar H, Holsboer-Trachsler E, Brand S. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).","journal-title":"Psychopharmacology"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/npp.2013.343","volume":"39","author":"Grant P.J.","year":"2014","unstructured":"Joseph LA, Farmer CA, Luckenbaugh DA, Lougee LC, Zarate CA, Swedo SE. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.","journal-title":"Neuropsychopharmacology"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.14m09123","volume":"76","author":"Pittenger C.","year":"2015","unstructured":"Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.","journal-title":"J Clin Psychiatry"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4088\/JCP.08m04605","volume":"70","author":"Koran L.M.","year":"2009","unstructured":"Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.","journal-title":"J Clin Psychiatry"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4088\/JCP.08m04269","volume":"70","author":"Vulink N.C.","year":"2009","unstructured":"Denys D, Fluitman SB, Meinardi JC, Westenberg HG. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.","journal-title":"J Clin Psychiatry"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/11635850-000000000-00000","volume":"26","author":"Askari N.","year":"2012","unstructured":"Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.","journal-title":"CNS Drugs"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YIC.0000000000000043","volume":"29","author":"Heidari M.","year":"2014","unstructured":"Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, Fallah J, Akhondzadeh S. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0035-1549929","volume":"48","author":"Shalbafan M.","year":"2015","unstructured":"Mohammadinejad P, Shariat SV, Alavi K, Zeinoddini A, Salehi M, Askari N, Akhondzadeh S. Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial.","journal-title":"Pharmacopsychiatry"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","volume":"47","author":"Ghaleiha A.","year":"2013","unstructured":"Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.","journal-title":"J Psychiatr Res"},{"key":"ref=131","author":"Emamzadehfard S.","year":"2016","unstructured":"Kamaloo A, Paydary K, Ahmadipour A, Zeinoddini A, Ghaleiha A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive compulsive disorder: randomized, double-blind, placebo-controlled study.","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jcpt.12370","volume":"41","author":"Paydary K.","year":"2016","unstructured":"Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.","journal-title":"J Clin Pharm Ther"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/158569","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/158569\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/158569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T04:49:44Z","timestamp":1608871784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/158569\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":126,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2019,1,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666171222163645","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}